PCMM
CRSP icon

Private Capital Management (Minnesota)’s CRISPR Therapeutics CRSP Stock Holding History

Private Capital Management (Minnesota)’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-5,000
Closed -$80K – 165
2017
Q2 		$80K Buy
+5,000
New +$82.6K 0.09% 165

Other funds holding CRSP

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
CCP
Clough Capital Partners Boston, Massachusetts $1.23B AUM 51.32% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
GTP
Global Thematic Partners New York $120M AUM 25.18% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
GIM
Granahan Investment Management Waltham, Massachusetts $2.81B AUM 83.9% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Private Capital Management (Minnesota)'s CRSP Position: Q3 2017 in Review

Private Capital Management (Minnesota) sold out of CRISPR Therapeutics (CRSP) in Q3 2017, closing a stake of 5,000 shares — an estimated $80K sold.

Private Capital Management (Minnesota) first reported a position in CRSP in Q2 2017 and held it in 1 quarter. The position peaked at $80K in Q2 2017. 64 funds tracked by Wall St. Rank hold CRSP as of Q3 2017.

  • Private Capital Management (Minnesota) reported no remaining CRISPR Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Private Capital Management (Minnesota) sold 5,000 CRISPR Therapeutics shares in Q3 2017, an estimated $80K.
  • Private Capital Management (Minnesota) first reported a position in CRISPR Therapeutics in Q2 2017 and held it in 1 quarter.
  • Private Capital Management (Minnesota)'s CRISPR Therapeutics position peaked at $80K in Q2 2017.
  • 64 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q3 2017.

Based on Private Capital Management (Minnesota)'s 13F filing for Q3 2017, filed 26 Oct 2017.